## Amendments to the Claims:

The following listing of claims will replace all prior versions, and listings, of claims in the application:

## Listing of Claims:

1.    (Currently Amended) A method for detecting tamoxifen-resistant breast cancer cells, comprising:

      a)    obtaining a sample suspected of containing tamoxifen-resistant breast cancer cells;

      b)    contacting said sample with an antibody that specifically binds to a polypeptide selected from the group consisting of tyrosine protein kinase receptor (TIE-2), endothelin-1 receptor (EDNRA), transforming growth factor β3 (TGFβ3), transforming growth factor receptor βIII (TGFRβIII), vascular permeability factor receptor (VEGFR1), vascular endothelin growth factor (VEGF) and basic fibroblast growth factor receptor (bFGFR), under conditions effective to bind said antibody and form a complex;

      c)    measuring [an] the amount of ~~at least one of the above polypeptides~~ said polypeptide present in said sample by quantitating the amount of said complex; and

      d)    comparing the amount of polypeptide present in said sample with the amount of polypeptide in estrogen-stimulated, tamoxifen-sensitive and tamoxifen-resistant breast cancer cells, wherein an increase in the amount of TIE-2, EDNRA, TGFβ3, TGFRβIII, VEGF or VEGFR1 polypeptide or a decrease in the amount of bFGFR polypeptide in said sample compared with the amount in estrogen-stimulated or tamoxifen-sensitive breast cancer cells indicates the

25413902.1

2

presence of tamoxifen-resistant breast cancer cells.

2.     (Withdrawn)   The method of claim 1, further comprising:

a)     measuring the amounts of two or more polypeptides selected from the group

consisting of TIE-2, EDNRA, TGFβ3, TGFRβIII, VEGFR1, VEGF and

bFGFR; and

b)     for each polypeptide, comparing the amount of said polypeptide present in said

sample with the amount of the same polypeptide present in estrogen-

stimulated, tamoxifen-sensitive and tamoxifen-resistant breast cancer cells.

3.     (Previously Presented)  The method of claim 1, further comprising providing a diagnosis

of tamoxifen-sensitive or tamoxifen-resistant breast cancer.

4.     (Previously Presented)  The method of claim 1, further comprising providing a prediction

of the existence or development of tamoxifen-resistant breast cancer.

5.     (Withdrawn)   A method of determining survival for an individual with breast cancer,

comprising determining the levels of TIE-2, EDNRA, TGFβ3, TGFRβIII, VEGFR1, VEGF or

bFGFR polypeptide in a breast cancer tissue sample from said individual, wherein the presence

of elevated levels of TIE-2, EDNRA, TGFβ3, TGFRβIII, VEGF or VEGFR1 polypeptide or

decreased levels of bFGFR polypeptide in said tissue sample relative to estrogen-stimulated or

tamoxifen sensitive breast cancer samples is associated with a decreased  survival of the

individual.

25413902.1

3

6-21.   (Canceled)

22.     (Previously Presented)   The method of claim 1, wherein the polypeptide is a TIE-2 polypeptide with a molecular weight of about 220 kDa.

23.     (Previously Presented)   The method of claim 22, wherein the tamoxifen-resistant breast cancer cells are MCF-7 cells.

24.     (Previously Presented)   The method of claim 22, further comprising providing a diagnosis of tamoxifen-sensitive or tamoxifen-resistant breast cancer.

25.     (Previously Presented)   The method of claim 22, further comprising providing a prediction of the existence or development of tamoxifen-resistant breast cancer.

25413902.1

4

PAGE 5/7 * RCVD AT 5/12/2004 7:09:21 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-1/0 * DNIS:8729306 * CSID:512 536 4598 * DURATION (mm-ss):02-06